FASN is one of the most attractive targets for NAFLD, given its role in controlling key mechanisms of NASH, i.e., hepatic DNL, inflammatory, and fibrogenic pathways (31, 32). This evidence concerns the gene FASN and metabolic dysfunction-associated steatohepatitis.